Clinical trials for malignant lymphoma in Japan

Japanese Journal of Clinical Oncology

Volumn 34, Issue 7, 2004, Pages 369-378

  Tobinai, Kensei ^a   Hotta, Tomomitsu ^b  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adult T cell leukemia lymphoma; Antibody therapy; Japan Clinical Oncology Group (JCOG); Malignant lymphoma; New agent

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CD20 ANTIBODY; CHIMERIC ANTIBODY; CHLORMETHINE; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; IRINOTECAN; METHOTREXATE; MONOCLONAL ANTIBODY; NEW DRUG; PENTOSTATIN; PREDNISONE; PROCARBAZINE; RANIMUSTINE; RITUXIMAB; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE; ZIDOVUDINE; CHOP PROTOCOL;

ADVANCED CANCER; ASTHENIA; B CELL LYMPHOMA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL STUDY; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INFUSION; DRUG METABOLISM; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL TOXICITY; HEADACHE; HEART ARRHYTHMIA; HERPES SIMPLEX; HUMAN; HYPERURICEMIA; ILEUS; INFECTION COMPLICATION; JAPAN; LEUKOPENIA; LIVER TOXICITY; LUNG ASPERGILLOSIS; LYMPHOCYTOPENIA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PAIN; PHLEBITIS; PRURITUS; RASH; REVIEW; RIGOR; SEPSIS; SIDE EFFECT; SWEATING; T CELL LEUKEMIA; T CELL LYMPHOMA; THROMBOCYTOPENIA; URTICARIA; VIRUS PNEUMONIA; MULTICENTER STUDY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; JAPAN; LYMPHOMA, NON-HODGKIN; MULTICENTER STUDIES; PREDNISONE; VINCRISTINE;

EID: 6044273407     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyh060     Document Type: Review

References (44)

1. Shimoyama M, Fukuda H, Saijo N, Yamaguchi N. Japan Clinical Oncology Group (JCOG). Jpn J Clin Oncol 1998;28:158-62.
2. Shimoyama M, Ota K, Kikuchi M, Yunoki K, Konda S, Takatsuki K, et al. Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M. J Clin Oncol 1988;6:128-41.
3. Shimoyama M, Ota K, Kikuchi M, Yunoki K, Konda S, Takatsuki K, et al. Major prognostic factors of adult patients with advanced T-cell lymphoma/ leukemia. J Clin Oncol 1988;6:1088-97.
4. Tobinai K, Shimoyama M, Minato K, Shirakawa S, Kobayashi T, Hotta T, et al. Japan Clinical Oncology Group phase II trial of second-generation 'LSG4 protocol' in aggressive T- and B-lymphoma: A new predictive model for T-and B-lymphoma. Proc Am Soc Clin Oncol 1994;13:378a (Abstract).
5. Kinoshita T, Hotta T, Tobinai K, Kobayashi T, Shirakawa S, Tomonaga M, et al. Randomized phase III trial investigating survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate- or high-grade non-Hodgkin's lymphoma: Japan Clinical Oncology Group (JCOG) Study (JCOG9002). Proc Am Soc Clin Oncol 2002;21: 378a (Abstract).
6. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-6.
7. Armitage JO, Cheson BD. Interpretation of clinical trials in diffuse large-cell lymphoma. J Clin Oncol 1988;6:1335-47.
8. Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma results of a tree-structured survival analysis. J Clin Oncol 1990;8:963-77.
9. Itoh K, Ohtsu T, Wakita H, Igarashi T, Ishizawa K, Onozawa Y, et al. Dose-escalation study of CHOP with or without prophylactic G-CSF in aggressive non-Hodgkin's lymphoma. Ann Oncol 2000;11:1241-7.
10. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-94.
11. Itoh K, Ohtsu T, Fukuda H, Sasaki Y, Ogura M, Morishima Y, et al. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505. Ann Oncol 2002;13:1347-55.
12. Hotta T, Shimakura Y, Ishizuka N, Fukuda H, Itoh K, Morishima Y, et al. Randomized phase III study of standard CHOP versus biweekly CHOP in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group study, JCOG9809. Proc Am Soc Clin Oncol 2003;22:565a (Abstract).
13. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994;84:2457-66.
14. Tobinai K, Kobayashi Y, Narabayashi M, Ogura M, Kagami Y, Morishima Y, et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. Ann Oncol 1998;9:527-34.
15. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33.
16. Igarashi T, Kobayashi Y, Ogura M, Kinoshita T, Ohtsu T, Sasaki Y, et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: A Japanese phase II study. Ann Oncol 2002; 13:928-43.
17. Coiffier B, Haioun C, Ketterer A, Engert A, Tilly H, Ma D, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 1998;92:1927-32.
18. Tobinai K, Igarashi T, Itoh K, Kobayashi Y, Taniwaki M, Ogura M, et al. Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol 2004;15:821-30.
19. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346: 235-42.
20. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma: A report from the Lymphoma Study Group (1984-87). Br J Haematol 1991;79:428-37.
21. Tobinai K, Shimoyama M, Inoue S, Takayasu S, Mikuni C, Kozuru M, et al. Phase I study of YK-176 (2′-deoxycoformycin) in patients with adult T-cell leukemia-lymphoma. Jpn J Clin Oncol 1992;22:164-71.
22. Shimoyama M. Chemotherapy of ATL. In: Takatsuki K, editor. Adult T-cell Leukaemia, Oxford: Oxford University Press, 1994:221-37.
23. Tsukasaki K, Tobinai K, Shimoyama M, Kozuru M, Uike N, Yamada Y, et al. Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group study (JCOG9109). Int J Hematol 2003;77:164-70.
24. Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara M, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukemia-lymphoma (ATL): Japan Clinical Oncology Group (JCOG) Study 9303. Br J Haematol 2001;113:375-82.
25. Takenaka T, Mikuni C, Miura A, Sasaki T, Suzuki H, Hotta T, et al. Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: A multicenter phase II study (JCOG 8905). Jpn J Clin Oncol 2000;30:146-52.
26. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-84.
27. Ogura M, Takenaka T, Kagami Y, Itoh K, Sasaki Y, Kinoshita T, et al. Phase II study of ABVd therapy for advanced stage Hodgkin's disease in Japan: Japan Clinical Oncology Group (JCOG) study (JCOG9305). Proc Am Soc Clin Oncol 2001;20:230b (Abstract).
28. Ogura M, Morishima Y, Itoh K, Ishizawa K, Kobayashi Y, Tobinai K, et al. Dacarbazine cannot be deleted from ABVD therapy for advanced Hodgkin lymphoma: Japan Clinical Oncology Group (JCOG) Study 9705. Proc Am Soc Clin Oncol 2003;22:573a (Abstract).
29. Ohno R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y, et al. An early phase II study of CPT-11: A new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 1990;8:1907-12.
30. Tsuda H, Takatsuki K, Ohno R, Masaoka T, Okada K, Shirakawa S, et al. A late phase II trial of a potent topoisomerase I inhibitor, CPT-11, in malignant lymphoma. Proc Am Soc Clin Oncol 1992;11:316 (Abstract).
31. Tsuda H, Takatsuki K, Ohno R, Masaoka T, Okada K, Shirakawa S, et al. Treatment of adult T-cell leukemia-lymphoma with irinotecan hydrochloride. Br J Cancer 1994;70:771-4.
32. Tobinai K, Hotta T, Saito H, Ohnishi K, Ohno R, Ogura M, et al. Combination phase I/II study of irinotecan hydrochloride and carboplatin in relapsed or refractory non-Hodgkin's lymphoma. Jpn J Clin Oncol 1996; 26:455-60.
33. Ohtsu T, Sasaki Y, Igarashi T, Murayama T, Kobayashi Y, Tobinai K. Unexpected hepatotoxicities in patients with non-Hodgkin's lymphoma treated with irinotecan (CPT-11) and etoposide. Jpn J Clin Oncol 1998;28: 502-6.
34. Gill PS, Harrington W, Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 1995;332:1744-8.
35. Hermine O, Blouscary D, Gessain A, Turlure P, Leblond V, Franck N, et al. Treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med 1995;332:1749-51.
36. Tobinai K, Kobayashi Y, Shimoyama M. Interferon alfa and zidovudine in adult T-cell leukemia-lymphoma. N Engl J Med 1995;333:1285-6 (Correspondence).
37. White JD, Wharfe G, Stewart DM, Maher VE, Eicher D, Herring B, et al. The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma. Leuk Lymphoma 2001;40:287-94.
38. Tobinai K, Ogura M, Hotta T, Kobayashi Y, Narabayashi M, Suzuki R, et al. Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies. Jpn J Clin Oncol 1997;27:146-53.
39. Tobinai K, Uike N, Saburi Y, Chou T, Etoh T, Masuda M, et al. Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma. Int J Hematol 2003;77:512-7.
40. Tobinai K, Kobayashi Y, Morishima Y, Ogura M, Uike N, Chou T, et al. Prolonged cytopenia and myelodysplastic syndrome after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphoma: results of Japanese phase II study. Proc Am Soc Clin Oncol 2001;20:228b (Abstract).
41. Tobinai K, Watanabe T, Hotta T, Ogawa Y, Sasaki Y, Minami H, et al. Phase I study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 2003;22:599a (Abstract).
42. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45.
43. Tobinai K. Monoclonal antibody therapy for B-cell lymphoma: Clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan. Int J Hematol 2002;76:411-9.
44. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3793-803.